By Maria Armental 
 

Edwards Lifesciences Corp. raised sales projections for the year, following stronger-than-expected second-quarter results.

The company now expects $5.2 billion to $5.4 billion in sales, up from its previous view of $4.9 billion to $5.3 billion in sales, and expects adjusted profit at the high end of the previous range of $2.07 to $2.27 a share.

This quarter, the medical-device company expects 50 cents to 56 cents a share in adjusted profit and $1.29 billion to $1.37 billion in sales, compared with analysts' projected 55 cents a share in profit and $1.3 billion in sales, according to FactSet.

"As patients and clinicians increasingly recognize the significant benefits of our less-invasive therapies, supported by the growing body of compelling evidence, we remain optimistic about the long-term growth opportunity," Chief Executive Michael A. Mussallem said in a statement.

 

Write to Maria Armental at maria.armental@wsj.com

 

(END) Dow Jones Newswires

July 29, 2021 16:39 ET (20:39 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Edwards Lifesciences (NYSE:EW)
Historical Stock Chart
From Aug 2021 to Sep 2021 Click Here for more Edwards Lifesciences Charts.
Edwards Lifesciences (NYSE:EW)
Historical Stock Chart
From Sep 2020 to Sep 2021 Click Here for more Edwards Lifesciences Charts.